To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT01785433
Last Updated: 2014-08-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
36 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-01-31
Study Completion Date
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this study is to assess and compare the pharmacokinetics (PK) of Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day), SPIRIVA®, HandiHaler®, (18 mcg/day) and Respimat® Soft Mist™ Inhaler (SMI) (5.0 mcg/day) following repeat dosing for 7 days in subjects with COPD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tiotropium Respimat Pharmacokinetic Study in COPD
NCT01222533
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE2
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02242266
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE2
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
NCT00239447
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
NCT00281567
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
NCT01126437
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This multicenter study consists of a Screening Visit (3 to 14 days prior to randomization); 4 multiple-dose (7-day) Treatment Periods, each consisting of a 2-night/3-day inpatient stay (Day 6 to Day 8); and a Final Visit. A washout period of at least 21 days will occur between each Treatment Period. The Final/ Early Termination Visit will occur 6-8 days following the last Treatment Period or upon early discharge from the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
COPD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment ABCD
The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
Treatment A: Tiotropium HFA BAI 4.5 mcg/day
Treatment B: Tiotropium HFA BAI 9.0 mcg/day
Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
Treatment D: Spiriva® Respimat® 5 mcg/day
Group Type
EXPERIMENTAL
Tiotropium HFA BAI 4.5 mcg
Intervention Type
DRUG
Tiotropium HFA BAI 9.0 mcg
Intervention Type
DRUG
SPIRIVA® HandiHaler® 18 mcg/day
Intervention Type
DRUG
Spiriva® Respimat® 5 mcg/day
Intervention Type
DRUG
Treatment BDAC
The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
Treatment B: Tiotropium HFA BAI 9.0 mcg/day
Treatment D: Spiriva® Respimat® 5 mcg/day
Treatment A: Tiotropium HFA BAI 4.5 mcg/day
Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
Group Type
EXPERIMENTAL
Tiotropium HFA BAI 4.5 mcg
Intervention Type
DRUG
Tiotropium HFA BAI 9.0 mcg
Intervention Type
DRUG
SPIRIVA® HandiHaler® 18 mcg/day
Intervention Type
DRUG
Spiriva® Respimat® 5 mcg/day
Intervention Type
DRUG
Treatment CADB
The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
Treatment A: Tiotropium HFA BAI 4.5 mcg/day
Treatment D: Spiriva® Respimat® 5 mcg/day
Treatment B: Tiotropium HFA BAI 9.0 mcg/day
Group Type
EXPERIMENTAL
Tiotropium HFA BAI 4.5 mcg
Intervention Type
DRUG
Tiotropium HFA BAI 9.0 mcg
Intervention Type
DRUG
SPIRIVA® HandiHaler® 18 mcg/day
Intervention Type
DRUG
Spiriva® Respimat® 5 mcg/day
Intervention Type
DRUG
Treatment DCBA
The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
Treatment D: Spiriva® Respimat® 5 mcg/day
Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
Treatment B: Tiotropium HFA BAI 9.0 mcg/day
Treatment A: Tiotropium HFA BAI 4.5 mcg/day
Group Type
EXPERIMENTAL
Tiotropium HFA BAI 4.5 mcg
Intervention Type
DRUG
Tiotropium HFA BAI 9.0 mcg
Intervention Type
DRUG
SPIRIVA® HandiHaler® 18 mcg/day
Intervention Type
DRUG
Spiriva® Respimat® 5 mcg/day
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tiotropium HFA BAI 4.5 mcg
Intervention Type
DRUG
Tiotropium HFA BAI 9.0 mcg
Intervention Type
DRUG
SPIRIVA® HandiHaler® 18 mcg/day
Intervention Type
DRUG
Spiriva® Respimat® 5 mcg/day
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Written informed consent signed and dated by the subject before conducting any study related procedure
2. Male or female subjects 40 -80 years of age, as of the Screening Visit
3. Diagnosis of COPD as defined by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Guidelines
4. A pre-bronchodilator Peak Inspiratory Flow (PIF) rate≥ 30 L/ min as measured with the In-Check™ DIAL training device.
5. A measured post-bronchodilator (ipratropium bromide) forced expiratory volume in one second (FEV1) \>30% and \<80% of predicted normal for height, age and gender at the Screening Visit (SV). Third National Health and Nutrition Examination Survey 1988-1994 (NHANES III) predicted values will be used and adjustments to predicted values will be made for African-American subjects.
6. A measured post-bronchodilator (ipratropium bromide) FEV1/Forced Vital Capacity (FVC) \<0.70 at the Screening Visit (SV)
7. If female, is currently not pregnant, breast feeding, or attempting to become pregnant (for 4 weeks before the Screening Visit (SV) and throughout the duration of the study), and is of
* Non-childbearing potential, defined as:
* ≥1 year post-menopausal or
* Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, or hysterectomy) or is of
* Childbearing potential, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control as defined below for the duration of the study:
* Systemic contraception used for ≥1 month prior to screening, including birth control pills, transdermal patch, vaginal ring, implants, or injectables or
* Double barrier methods (condoms, cervical cap, diaphragm, and vaginal contraceptive film with spermicide) or
* Intrauterine device (IUD) with a low failure rate defined as \<1% per year (use of copper IUDs are excluded) or is of
* Childbearing potential and not sexually active, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control as defined above for the duration of the study, in the event the subject becomes sexually active
8. Current or ex-smoker with ≥10 pack-year smoking history
9. Subject is free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the study
10. Able to perform technically acceptable and reproducible spirometry per study guidelines as defined in the protocol and study procedures manual.
11. Able to demonstrate the proper inhalation techniques required for correct use of all delivery devices required in the study
12. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and being compliant with all study requirements
2. Male or female subjects 40 -80 years of age, as of the Screening Visit
3. Diagnosis of COPD as defined by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Guidelines
4. A pre-bronchodilator Peak Inspiratory Flow (PIF) rate≥ 30 L/ min as measured with the In-Check™ DIAL training device.
5. A measured post-bronchodilator (ipratropium bromide) forced expiratory volume in one second (FEV1) \>30% and \<80% of predicted normal for height, age and gender at the Screening Visit (SV). Third National Health and Nutrition Examination Survey 1988-1994 (NHANES III) predicted values will be used and adjustments to predicted values will be made for African-American subjects.
6. A measured post-bronchodilator (ipratropium bromide) FEV1/Forced Vital Capacity (FVC) \<0.70 at the Screening Visit (SV)
7. If female, is currently not pregnant, breast feeding, or attempting to become pregnant (for 4 weeks before the Screening Visit (SV) and throughout the duration of the study), and is of
* Non-childbearing potential, defined as:
* ≥1 year post-menopausal or
* Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, or hysterectomy) or is of
* Childbearing potential, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control as defined below for the duration of the study:
* Systemic contraception used for ≥1 month prior to screening, including birth control pills, transdermal patch, vaginal ring, implants, or injectables or
* Double barrier methods (condoms, cervical cap, diaphragm, and vaginal contraceptive film with spermicide) or
* Intrauterine device (IUD) with a low failure rate defined as \<1% per year (use of copper IUDs are excluded) or is of
* Childbearing potential and not sexually active, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control as defined above for the duration of the study, in the event the subject becomes sexually active
8. Current or ex-smoker with ≥10 pack-year smoking history
9. Subject is free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the study
10. Able to perform technically acceptable and reproducible spirometry per study guidelines as defined in the protocol and study procedures manual.
11. Able to demonstrate the proper inhalation techniques required for correct use of all delivery devices required in the study
12. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and being compliant with all study requirements
Exclusion Criteria
1. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit (for eligible subjects only, if applicable).
2. History or current evidence (as determined by medical history, physical examination, clinical laboratory assessments and ECG) of a clinically significant or uncontrolled disease including, but not limited to: cardiovascular (e.g., uncontrolled hypertension, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal, haematological, neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal (e.g., poorly controlled peptic ulcer, gastroesophageal reflux disease) or pulmonary (other than COPD such as asthma, sarcoidosis, non-cystic fibrosis (CF) bronchiectasis, cystic fibrosis, bronchopulmonary dysplasia or a diagnosis of alpha 1-antitrypsin deficiency). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which could affect the endpoint analysis if the disease/condition exacerbated during the study.
3. History of and/or current diagnosis of asthma
4. History of a life-threatening COPD exacerbation - defined for this protocol as a COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures
5. Thoracotomy with pulmonary resection
6. Current congestive heart failure, history or current evidence of myocardial infarction (within 3 yrs of the Screening Visit \[SV\]), or history or current evidence of ischemic heart disease, including a diagnosis on screening ECG.
7. History or current evidence of clinically significant cardiac arrhythmia, including a diagnosis on screening ECG.
8. Presence of angle-closure glaucoma
9. History of malignancy (excluding basal cell carcinoma) within the past 5 years, regardless of the clinical significance or current stability of the disease
10. Known history or any current evidence of renal impairment or urinary retention (e.g., bladder outlet obstruction). This includes abnormal renal function test results at screening.
11. Presence of symptomatic prostatic hyperplasia
12. History of silent infections, including positive tests for human immunodeficiency virus 1, human immunodeficiency virus 2, Hepatitis B, Hepatitis C, or tuberculosis.
13. Occurrence of any upper or lower respiratory infection, including but not limited to the common cold and flu, sinusitis,tonsillitis, pneumonia, bronchitis, or an ear infection (including otitis media and externa) which is not resolved by 14 days prior to randomization
14. Occurrence of a COPD exacerbation which is not resolved by 14 days prior to randomization i. Note: An exacerbation of COPD is defined as any worsening of the subject's baseline COPD symptoms requiring any treatment other than rescue albuterol/salbutamol/ipratropium or the subject's regular maintenance treatment. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization, a change in subject's regular, or the addition of other medications used to treat COPD symptoms.
15. Subjects who require oxygen therapy and in the investigator's opinion, will be unable to abstain from the use of oxygen therapy during testing
16. Subjects who have started or stopped an exercise rehabilitation program within 4 weeks of the Screening Visit (SV)
17. Known or suspected hypersensitivity or idiosyncratic reaction to tiotropium, or to any ingredients used in the study medication formulations
18. Severe allergy to milk protein
19. Significant adverse drug reactions, including allergy or hypersensitivity reactions, to atropine or any anticholinergic substance related pharmacologically to atropine (e.g., ipratropium or oxitropium)
20. Use of any prohibited concomitant medications within the prescribed (per protocol) withdrawal periods prior to the Screening Visit
21. Treatment with orally administered (excluding orally inhaled) β-adrenergics (i.e., oral salbutamol)
22. Treatment with β-adrenergic receptor antagonists (e.g. non-selective β-receptor blocking agents like β-blocking anti-hypertensive products) administered by any route. The single exception is that cardioselective β1-adrenergic receptor antagonists (e.g. atenolol, metoprolol, bisoprolol) are permitted provided that subjects have been on a stable dose for at least 1 week prior to the screening visit and subjects are expected to be able to maintain the same dose throughout the study.
23. Treatment with drugs commonly recognized to prolong the QTc interval (e.g., quinolones, amiodarone, disopyramide, quinidine, sotalol, chlorpromazine, haloperidol, ketoconazole, terfenadine, cisapride and terodiline)
24. Treatment with any known cytochrome P450 (CYP) 2D6 or cytochrome P450 (CYP) 3A4 inhibitors (e.g., quinidine, ketoconazole and gestodene) within 30 days prior to the Screening Visit (SV)
25. Initiation or change in dose of inhaled corticosteroids within the last 6 weeks prior to the Screening Visit (SV), and /or not expected to maintain a stable dose of inhaled corticosteroids during the course of the study.
26. Initiation or change in dose of oral or systemic corticosteroids within the last 6 weeks prior to the Screening Visit (SV) , unable to maintain a stable dose of oral or systemic corticosteroids during the course of the study, or a dose of oral or systemic corticosteroids in excess of the equivalent of 10 mg of prednisone per day. \[Note that oral steroid bursts completed 6 weeks or more prior to screening are acceptable.\]
27. Exposure to any investigational drug within 30 days or six half-lives (whichever is greater) prior to the Screening Visit (SV)
28. Plans to donate or has donated plasma or blood within 1 month prior to the Screening Visit (SV). This does not include small blood volumes taken for diagnostic purposes. Plans to donate plasma or blood within 3 months following study completion
29. Has a history of alcohol and/or substance abuse within the past 5 years
30. Vulnerable subjects (e.g., persons kept in detention)
31. The subject is an employee of the study site or has an immediate family member or household member involved with the conduct of the study (including participation in the study).
2. History or current evidence (as determined by medical history, physical examination, clinical laboratory assessments and ECG) of a clinically significant or uncontrolled disease including, but not limited to: cardiovascular (e.g., uncontrolled hypertension, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal, haematological, neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal (e.g., poorly controlled peptic ulcer, gastroesophageal reflux disease) or pulmonary (other than COPD such as asthma, sarcoidosis, non-cystic fibrosis (CF) bronchiectasis, cystic fibrosis, bronchopulmonary dysplasia or a diagnosis of alpha 1-antitrypsin deficiency). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which could affect the endpoint analysis if the disease/condition exacerbated during the study.
3. History of and/or current diagnosis of asthma
4. History of a life-threatening COPD exacerbation - defined for this protocol as a COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures
5. Thoracotomy with pulmonary resection
6. Current congestive heart failure, history or current evidence of myocardial infarction (within 3 yrs of the Screening Visit \[SV\]), or history or current evidence of ischemic heart disease, including a diagnosis on screening ECG.
7. History or current evidence of clinically significant cardiac arrhythmia, including a diagnosis on screening ECG.
8. Presence of angle-closure glaucoma
9. History of malignancy (excluding basal cell carcinoma) within the past 5 years, regardless of the clinical significance or current stability of the disease
10. Known history or any current evidence of renal impairment or urinary retention (e.g., bladder outlet obstruction). This includes abnormal renal function test results at screening.
11. Presence of symptomatic prostatic hyperplasia
12. History of silent infections, including positive tests for human immunodeficiency virus 1, human immunodeficiency virus 2, Hepatitis B, Hepatitis C, or tuberculosis.
13. Occurrence of any upper or lower respiratory infection, including but not limited to the common cold and flu, sinusitis,tonsillitis, pneumonia, bronchitis, or an ear infection (including otitis media and externa) which is not resolved by 14 days prior to randomization
14. Occurrence of a COPD exacerbation which is not resolved by 14 days prior to randomization i. Note: An exacerbation of COPD is defined as any worsening of the subject's baseline COPD symptoms requiring any treatment other than rescue albuterol/salbutamol/ipratropium or the subject's regular maintenance treatment. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization, a change in subject's regular, or the addition of other medications used to treat COPD symptoms.
15. Subjects who require oxygen therapy and in the investigator's opinion, will be unable to abstain from the use of oxygen therapy during testing
16. Subjects who have started or stopped an exercise rehabilitation program within 4 weeks of the Screening Visit (SV)
17. Known or suspected hypersensitivity or idiosyncratic reaction to tiotropium, or to any ingredients used in the study medication formulations
18. Severe allergy to milk protein
19. Significant adverse drug reactions, including allergy or hypersensitivity reactions, to atropine or any anticholinergic substance related pharmacologically to atropine (e.g., ipratropium or oxitropium)
20. Use of any prohibited concomitant medications within the prescribed (per protocol) withdrawal periods prior to the Screening Visit
21. Treatment with orally administered (excluding orally inhaled) β-adrenergics (i.e., oral salbutamol)
22. Treatment with β-adrenergic receptor antagonists (e.g. non-selective β-receptor blocking agents like β-blocking anti-hypertensive products) administered by any route. The single exception is that cardioselective β1-adrenergic receptor antagonists (e.g. atenolol, metoprolol, bisoprolol) are permitted provided that subjects have been on a stable dose for at least 1 week prior to the screening visit and subjects are expected to be able to maintain the same dose throughout the study.
23. Treatment with drugs commonly recognized to prolong the QTc interval (e.g., quinolones, amiodarone, disopyramide, quinidine, sotalol, chlorpromazine, haloperidol, ketoconazole, terfenadine, cisapride and terodiline)
24. Treatment with any known cytochrome P450 (CYP) 2D6 or cytochrome P450 (CYP) 3A4 inhibitors (e.g., quinidine, ketoconazole and gestodene) within 30 days prior to the Screening Visit (SV)
25. Initiation or change in dose of inhaled corticosteroids within the last 6 weeks prior to the Screening Visit (SV), and /or not expected to maintain a stable dose of inhaled corticosteroids during the course of the study.
26. Initiation or change in dose of oral or systemic corticosteroids within the last 6 weeks prior to the Screening Visit (SV) , unable to maintain a stable dose of oral or systemic corticosteroids during the course of the study, or a dose of oral or systemic corticosteroids in excess of the equivalent of 10 mg of prednisone per day. \[Note that oral steroid bursts completed 6 weeks or more prior to screening are acceptable.\]
27. Exposure to any investigational drug within 30 days or six half-lives (whichever is greater) prior to the Screening Visit (SV)
28. Plans to donate or has donated plasma or blood within 1 month prior to the Screening Visit (SV). This does not include small blood volumes taken for diagnostic purposes. Plans to donate plasma or blood within 3 months following study completion
29. Has a history of alcohol and/or substance abuse within the past 5 years
30. Vulnerable subjects (e.g., persons kept in detention)
31. The subject is an employee of the study site or has an immediate family member or household member involved with the conduct of the study (including participation in the study).
Minimum Eligible Age
40 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teva Investigational Site 32170
Berlin, , Germany
Site Status
Teva Investigational Site 32169
Gauting, , Germany
Site Status
Teva Investigational Site 32171
Großhansdorf, , Germany
Site Status
Teva Investigational Site 32167
Mannheim, , Germany
Site Status
Teva Investigational Site 32168
Wiesbaden, , Germany
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TBB-COPD-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD
NCT02541006
COMPLETED
PHASE4
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02175342
COMPLETED
PHASE2
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT05986591
COMPLETED
PHASE3
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
NCT01072396
COMPLETED
PHASE4
A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease
NCT02203474
WITHDRAWN
PHASE2
Airway Effects of Tiotropium in Patients With COPD
NCT02683668
COMPLETED
PHASE3
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients
NCT00620516
COMPLETED
Bioequivalence Study of Tiotropium Bromide Inhalation Powder
NCT05161156
COMPLETED
PHASE3
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
NCT01662986
COMPLETED
PHASE4
Tiotropium Handihaler vs. Tiotropium Respimat in COPD
NCT05838703
WITHDRAWN
PHASE2
Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers
NCT02254174
COMPLETED
PHASE1
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00274547
COMPLETED
PHASE3
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
NCT01566773
COMPLETED
PHASE2
Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172456
COMPLETED
PHASE3
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
NCT00144196
COMPLETED
PHASE4
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
NCT06326671
ACTIVE_NOT_RECRUITING
PHASE1
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
NCT00144339
COMPLETED
PHASE3
Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
NCT02172521
COMPLETED
Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema
NCT00570544
COMPLETED
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03118765
COMPLETED
PHASE2
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00292448
COMPLETED
PHASE2
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
NCT01663987
COMPLETED
PHASE4
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00662740
TERMINATED
PHASE3
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00240435
COMPLETED
PHASE3
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
NCT01483625
COMPLETED
PHASE4